Search

Your search keyword '"Naka, Norifumi"' showing total 17 results
Start Over Author "Naka, Norifumi" Language undetermined
17 results on '"Naka, Norifumi"'

1. Additional file 1: of Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304

Author

Tanaka, Kazuhiro, Junki Mizusawa, Naka, Norifumi, Kawai, Akira, Katagiri, Hirohisa, Hiruma, Toru, Matsumoto, Yoshihiro, Tsuchiya, Hiroyuki, Nakayama, Robert, Hatano, Hiroshi, Emori, Makoto, Munenori Watanuki, Yoshida, Yukihiro, Okamoto, Takeshi, Abe, Satoshi, Asanuma, Kunihiro, Yokoyama, Ryohei, Hiraga, Hiroaki, Yonemoto, Tsukasa, Morii, Takeshi, Ae, Keisuke, Nagano, Akihito, Yoshikawa, Hideki, Fukuda, Haruhiko, Ozaki, Toshifumi, and Yukihide Iwamoto

Abstract

Table S1. Names of the Institutional Review Boards of participating institutions. (DOCX 12 kb)

Published
2019
Full Text
View/download PDF

2. Additional file 9: Figure S8. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Subjects
stomatognathic diseases, stomatognathic system, macromolecular substances
Abstract

Immunohistological staining of anti-vimentin and anti-cytokeratin (AE1/AE3) antibodies in SYO-1 xenograft tumours for each treatment group (× 400). Vimentin was diffusely present in both spindle and epithelial components, whereas epithelial cells expressed cytokeratin (AE1/AE3) relatively higher than spindle tumour cells. Scale bars, 100 μm. (PPTX 7779 kb)

Published
2017
Full Text
View/download PDF

3. Additional file 3: Figure S3. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

The weight of Yamato-SS and SYO-1 xenograft tumours for each treatment group. Bars represent the SE. * p

Published
2017
Full Text
View/download PDF

4. Additional file 1: Figure S1. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

(A) Expression of c-MET in Yamato-SS, SYO-1 and HS-SY-II cells after treatment with anti-c-MET siRNAs or a control siRNA. (B) PDGFRα expression in Yamato-SS, SYO-1 and HS-SY-II cells after treatment with anti-PDGFRα siRNAs or a control siRNA. (PPTX 166 kb)

Published
2017
Full Text
View/download PDF

5. Additional file 5: Figure S5. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

Immunoblot analysis of Yamato-SS xenografts. Mice bearing Yamato-SS cells were treated with 50 or 200-mg/kg TAS-115 or control orally once a day for 4 weeks, euthanized 3 h after final administration and subjected to immunoblot analysis. (PPTX 117 kb)

Published
2017
Full Text
View/download PDF

7. Additional file 2: Figure S2. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

SYO-1 and HS-SY-II (PDGFRα-dependent) SS cells were treated with 0.001–10 μM of TAS-115 or control (0.1% DMSO) for 3 h, followed by an additional treatment with 10-ng/ml rhPDGF-BB for the last 15 min. (PPTX 178 kb)

Published
2017
Full Text
View/download PDF

8. Additional file 7: Figure S7. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Subjects
cardiovascular system
Abstract

(A) Immunohistological staining of anti-CD31 antibody in Yamato-SS xenograft tumours for each treatment group (× 200). Scale bars, 100 μm. (B) Microvascular density (MVD) of Yamato-SS xenograft tumours. Bars represent the SD. * p

Published
2017
Full Text
View/download PDF

9. Additional file 2: Figure S2. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

SYO-1 and HS-SY-II (PDGFRα-dependent) SS cells were treated with 0.001–10 μM of TAS-115 or control (0.1% DMSO) for 3 h, followed by an additional treatment with 10-ng/ml rhPDGF-BB for the last 15 min. (PPTX 178 kb)

Published
2017
Full Text
View/download PDF

10. Additional file 6: Figure S6. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

(A) Light microscopic findings of Yamato-SS xenograft tumours for each treatment group (× 200). Scale bars, 100 μm. The tumours had both spindle cell components (upper panels) and epithelial cell components (lower panels). (B) Light microscopic findings of SYO-1 xenograft tumours for each treatment group (× 200). Scale bars, 100 μm. The tumours had both spindle cell components (upper panels) and epithelial cell components (lower panels). (PPTX 7168 kb)

Published
2017
Full Text
View/download PDF

11. Additional file 9: Figure S8. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Subjects
stomatognathic diseases, stomatognathic system, macromolecular substances
Abstract

Immunohistological staining of anti-vimentin and anti-cytokeratin (AE1/AE3) antibodies in SYO-1 xenograft tumours for each treatment group (× 400). Vimentin was diffusely present in both spindle and epithelial components, whereas epithelial cells expressed cytokeratin (AE1/AE3) relatively higher than spindle tumour cells. Scale bars, 100 μm. (PPTX 7779 kb)

Published
2017
Full Text
View/download PDF

12. Additional file 6: Figure S6. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

(A) Light microscopic findings of Yamato-SS xenograft tumours for each treatment group (× 200). Scale bars, 100 μm. The tumours had both spindle cell components (upper panels) and epithelial cell components (lower panels). (B) Light microscopic findings of SYO-1 xenograft tumours for each treatment group (× 200). Scale bars, 100 μm. The tumours had both spindle cell components (upper panels) and epithelial cell components (lower panels). (PPTX 7168 kb)

Published
2017
Full Text
View/download PDF

13. Additional file 1: Figure S1. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

(A) Expression of c-MET in Yamato-SS, SYO-1 and HS-SY-II cells after treatment with anti-c-MET siRNAs or a control siRNA. (B) PDGFRα expression in Yamato-SS, SYO-1 and HS-SY-II cells after treatment with anti-PDGFRα siRNAs or a control siRNA. (PPTX 166 kb)

Published
2017
Full Text
View/download PDF

14. Additional file 4: Figure S4. of Therapeutic potential of TAS-115 via c-MET and PDGFRÎą signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

Body weight of mice bearing Yamato-SS and SYO-1 cells for each treatment group. Bars represent the SE. (PPTX 64Â kb)

Published
2017
Full Text
View/download PDF

15. Additional file 4: Figure S4. of Therapeutic potential of TAS-115 via c-MET and PDGFRÎą signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

Body weight of mice bearing Yamato-SS and SYO-1 cells for each treatment group. Bars represent the SE. (PPTX 64Â kb)

Published
2017
Full Text
View/download PDF

16. Additional file 7: Figure S7. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Subjects
cardiovascular system
Abstract

(A) Immunohistological staining of anti-CD31 antibody in Yamato-SS xenograft tumours for each treatment group (× 200). Scale bars, 100 μm. (B) Microvascular density (MVD) of Yamato-SS xenograft tumours. Bars represent the SD. * p

Published
2017
Full Text
View/download PDF

17. Additional file 5: Figure S5. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Author

Shutaro Yamada, Imura, Yoshinori, Nakai, Takaaki, Nakai, Sho, Yasuda, Naohiro, Kaneko, Keiko, Hidetatsu Outani, Takenaka, Satoshi, Hamada, Kenichiro, Myoui, Akira, Nobuhito Araki, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, and Naka, Norifumi

Abstract

Immunoblot analysis of Yamato-SS xenografts. Mice bearing Yamato-SS cells were treated with 50 or 200-mg/kg TAS-115 or control orally once a day for 4 weeks, euthanized 3 h after final administration and subjected to immunoblot analysis. (PPTX 117 kb)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results